-
Founded in:
1994-11-24 -
Country:
China -
Address:
No. 3601, Tuanjie Road, Qingdao Economic and Technological Development Zone -
Tax NO.:
91370211614316886Y -
Registered Funds:
62.748 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Acetaminophen |
It can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects
More
It can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects |
103-90-2 | 68 | |
| Dextromethorphan hydrobromide monohydrate |
It can inhibit the cough center and produce an antitussive effect
More
It can inhibit the cough center and produce an antitussive effect |
0 | ||
| (1S,2S)-(+)-Pseudoephedrine hydrochloride |
It can selectively constrict the blood vessels in the upper respiratory tract, eliminate nasal mucosal congestion, and relieve nasal congestion and runny nose.
More
It can selectively constrict the blood vessels in the upper respiratory tract, eliminate nasal mucosal congestion, and relieve nasal congestion and runny nose. |
0 | ||
| Chlorphenamine maleate |
It is an antihistamine that can eliminate or alleviate allergic symptoms such as tearing, runny nose, sneezing, etc. caused by colds.
More
It is an antihistamine that can eliminate or alleviate allergic symptoms such as tearing, runny nose, sneezing, etc. caused by colds. |
113-92-8 | 28 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Alfacalcidol |
Extract from the above information
More
Extract from the above information |
41294-56-8 | 14 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| MOUTAN CORTEX |
|
0 | ||
| Monopatassium glycyrrhizinate |
|
0 | ||
| Abamectin+β-Cypermethrin,W.P. |
|
0 | ||
| COPTIDISRHIZOMA |
|
0 | ||
| Linderae Radix |
|
0 | ||
| AURANTII FRUCTUS |
|
0 | ||
| Aucklandiae Radix |
|
0 | ||
| MYLABRIS |
|
0 | ||
| Zedoary turmeric |
|
0 | ||
| Rhizoma Sparganii Extract |
|
0 | ||
| Rhizoma Curcumae |
|
0 | ||
| Yanhusuo |
|
0 | ||
| Astragalus (processed) |
|
0 | ||
| Salvia Root P.E Tanshinone IIA 20% |
|
0 | ||
| Paeoniae Rubra |
|
0 | ||
| Riligustilide |
|
89354-45-0 | 0 | |
| Angelicae Sinensis Radix |
|
0 | ||
| CARTHAMI FLOS |
|
0 | ||
| PERSICAE SEMEN |
|
0 | ||
| Asari Radix et Rhizoma |
|
0 | ||
| Cassia Aurantium P.E Catechins 8% HPLC |
|
0 | ||
| EUODIAE FRUCTUS |
|
0 | ||
| Cmnamomi Mmulus |
|
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| MOUTAN CORTEX |
|
0 | ||
| Monopatassium glycyrrhizinate |
|
0 | ||
| Abamectin+β-Cypermethrin,W.P. |
|
0 | ||
| COPTIDISRHIZOMA |
|
0 | ||
| Linderae Radix |
|
0 | ||
| AURANTII FRUCTUS |
|
0 | ||
| Aucklandiae Radix |
|
0 | ||
| MYLABRIS |
|
0 | ||
| Zedoary turmeric |
|
0 | ||
| Rhizoma Sparganii Extract |
|
0 | ||
| Rhizoma Curcumae |
|
0 | ||
| Yanhusuo |
|
0 | ||
| Astragalus (processed) |
|
0 | ||
| Salvia Root P.E Tanshinone IIA 20% |
|
0 | ||
| Paeoniae Rubra |
|
0 | ||
| Riligustilide |
|
89354-45-0 | 0 | |
| Angelicae Sinensis Radix |
|
0 | ||
| CARTHAMI FLOS |
|
0 | ||
| PERSICAE SEMEN |
|
0 | ||
| Asari Radix et Rhizoma |
|
0 | ||
| Cassia Aurantium P.E Catechins 8% HPLC |
|
0 | ||
| EUODIAE FRUCTUS |
|
0 | ||
| Cmnamomi Mmulus |
|
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Calcitriol |
Calcitriol is one of the most important active metabolites of vitamin D3, usually converted from its precursor 25-hydroxyvitamin D3 (25-HCC) in the kidney. Calcitriol promotes intestinal absorption of calcium and regulates bone mineralization. The pharmacological effect of a single dose of calcitriol can last for about 3 to 5 days. The key role of calcitriol in regulating calcium balance, including the stimulation of osteoblast activity in bones, provides a sufficient pharmacological basis for the treatment of osteoporosis. For patients with renal osteodystrophy, oral administration of this product restores the ability of the intestine to absorb calcium to normal, corrects hypocalcemia, and excessive blood alkaline phosphatase and parathyroid hormone concentrations. This product can relieve bone and muscle pain and correct histological changes that occur in patients with osteitis fibrosa and other mineral deficiency. For patients with vitamin D-dependent rickets, the level of calcitriol in the blood is reduced or absent. Due to insufficient production of calcitriol in the kidney, this product can be considered as an alternative treatment. In patients with vitamin D-resistant rickets and hypophosphatemia, blood calcium levels are reduced. Treatment with this product can reduce tubular elimination of phosphate and, combined with treatment with phosphate preparations, restore bone growth.
More
Calcitriol is one of the most important active metabolites of vitamin D3, usually converted from its precursor 25-hydroxyvitamin D3 (25-HCC) in the kidney. Calcitriol promotes intestinal absorption of calcium and regulates bone mineralization. The pharmacological effect of a single dose of calcitriol can last for about 3 to 5 days. The key role of calcitriol in regulating calcium balance, including the stimulation of osteoblast activity in bones, provides a sufficient pharmacological basis for the treatment of osteoporosis. For patients with renal osteodystrophy, oral administration of this product restores the ability of the intestine to absorb calcium to normal, corrects hypocalcemia, and excessive blood alkaline phosphatase and parathyroid hormone concentrations. This product can relieve bone and muscle pain and correct histological changes that occur in patients with osteitis fibrosa and other mineral deficiency. For patients with vitamin D-dependent rickets, the level of calcitriol in the blood is reduced or absent. Due to insufficient production of calcitriol in the kidney, this product can be considered as an alternative treatment. In patients with vitamin D-resistant rickets and hypophosphatemia, blood calcium levels are reduced. Treatment with this product can reduce tubular elimination of phosphate and, combined with treatment with phosphate preparations, restore bone growth. |
32222-06-3 | 21 |